There was no significant difference in neutropenia rates between the two groups when compared at week 14 of treatment. Recent findings In a recent study suggest that bb2121 is as safe as lenalidomide +/- dexamethasone in patients with relapsed multiple myeloma who received prior chemotherapy.
Lenalidomide and bb2121 are frequently used in combination with other agents. A minority of patients are enrolled in clinical trials of lenalidomide; however, more than 90% of patients treated with lenalidomide are enrolled in clinical trials of bb2121. A larger proportion of patients receiving bb2121 have received other therapy than lenalidomide.
Clinical trials provide important information for patients about their disease and treatment options. A multidisciplinary approach involving all relevant clinicians is crucial if patients are to make informed decisions about clinical trials.
The combination of lenalidomide and bb2121 resulted in better response rates compared to either agent alone. The safety profile was comparable between individuals receiving lenalidomide plus bb2121 or lenalidomide monotherapy. Lenalidomide plus bb2121 appears to provide a safe and effective option for the treatment of MM.
Multiple myeloma involves both blood cells and bone marrow cells. The bone marrow cells go through a process called clonal selection and proliferation, which is what causes myeloma to grow. In order for myeloma to spread, it must be present in the bloodstream. This is why it affects both the blood and bone marrow. It is now believed that bone marrow cells are more important than blood cells when initiating and growing myeloma. However, this does not mean that there will never be any effect on the blood system. Current treatments do not allow for complete control of myeloma; therefore, there needs to be research in order to develop new methods of treating myeloma.
Patients with RR MM responded well to lenalidomide plus bb2121. The prominent role of bb2121 In a recent study supports its use in combination regimens for RR MM.
The clinical data reported in this review support the use of lenalidomide with bortezomib for elderly patients with relapsed or refractory MM. These data also show that lenalidomide can be safely administered on an outpatient basis leading to the conclusion that lenalidomide with bortezomib is a rational regimen for treatment of elderly patients with relapsed or refractory MM.
There is no cure for MM. Treatment protocols should include chemotherapy, radiotherapy, and autologous stem cell transplantation (ASCT). Autologous stem cell transplantation was the most effective treatment strategy found In a recent study. The use of ASCT may help to reduce progression-free survival and overall survival in newly diagnosed MM patients. However, studies have shown that even in patients who receive ASCT, death from other causes occurs during the posttransplant period.
Lenalidomide and bb2121 were associated with majority of the common adverse events. The safety profile of lenalidomide and bb2121 was similar to previous reports on lenalidomide monotherapy.
Multiple myeloma is a deadly and highly treatable disease, but unfortunately, only 50% of people diagnosed with multiple myeloma survive for five years after diagnosis.(https://www.withpower.com/myeloma-patient-support) In order to find the best possible treatment, it’s important that doctors develop a thorough understanding of the different factors that contribute to multiple myeloma's occurrence and progression. [Find the best clinical trial]\n
In a typical Caucasian population, MM affects about 2 people per 10,000 person-years. The median age at diagnosis is 63 years; median survival time is 8.2 years. In North America, MM occurs most commonly in elderly men, but has been reported in women and children. In Europe, MM tends to occur later in life and with lower survival rates. There is no clear relationship between race and presentation. MM occurs more frequently in African Americans than in Caucasians. The incidence of MM is increasing in some countries. This increase is similar to that observed for other types of cancers, possibly because it is related to lifestyle factors such as cigarette smoking and obesity.